“Clinical trials require teamwork from both patients and clinicians, and through this collaboration, we will bring forward new NET treatments in the coming 10 years,” he says.
He is also research group that is seeking funding for a major national trial for 85 patients examining whether combining radioactive PRRT (Lutate) therapy with chemotherapy can improve outcomes. “I think this is an internationally practice-changing trial,” he says. David says patients accessing clinical trials as therapy is really important and as he is on international NET committees, he has a sense of ‘what’s next’ for patients, which includes new nuclear medicine treatments and imaging.
When considered individually, NETs are relatively uncommon types of lung, bowel and pancreatic cancer. However, when combined there are about 5,000 NETS cases diagnosed each year
placing it among the top 10 most common cancers in Australia.
Associate Professor David Chan
27
Made with FlippingBook - professional solution for displaying marketing and sales documents online